1. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
   Nadine Aschmoneit et al, 2021, Scientific Reports CrossRef
2. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
   Nadine Aschmoneit et al, 2021, Journal for ImmunoTherapy of Cancer CrossRef
3. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
   Huilan Zeng et al, 2024, Cancer Drug Resistance CrossRef
4. HER3 in cancer: from the bench to the bedside
   Lucía Gandullo-Sánchez et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef